North America Preclinical Imaging Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2023 –2030 |
 Tamaño del mercado (año base) |
USD 1,213,520.05 million |
 Tamaño del mercado (año de pronóstico) |
USD 2,005,475.12 million |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
North America Preclinical Imaging Market, By Product (Systems and Services), Reagents (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, and Preclinical CT Contrast Agents), Application (Research and Development, Drug Discovery, Bio-Distribution, Cancer Cell Detection, Bio-Markers, and Others), End User (Contract Research Organization, Pharmaceutical & Biotech Companies, Academic & Government Research Institutes, Diagnostics Center, and Others) – Industry Trends and Forecast to 2030.
North America Preclinical Imaging Market Analysis and Size
The North America preclinical imaging market is the industry involved in providing imaging solutions and technologies for conducting research and experimentation on animals (usually rodents) in the preclinical stage of drug development and medical research. These imaging techniques are crucial for assessing the safety and efficacy of potential drug candidates and medical treatments before they advance to clinical trials involving human subjects. Preclinical imaging allows researchers and pharmaceutical companies to evaluate the effects of drug candidates on living organisms before moving to human trials. This helps in identifying potential issues, optimizing dosage regimens, and reducing the risk of adverse effects in later stages.
Data Bridge Market Research analyzes that the North America preclinical imaging market is expected to reach the value of USD 2,005,475.12 thousand by 2030 from USD 1,213,520.05 thousand in 2022 at a CAGR of 6.7 % during the forecast period.
This market report also covers pricing analysis and technological advancements in depth.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Thousand |
|
Segments Covered |
Product (Systems and Services), Reagents (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, and Preclinical CT Contrast Agents), Application (Research and Development, Drug Discovery, Bio-Distribution, Cancer Cell Detection, Bio-Markers, and Others), End User (Contract Research Organization, Pharmaceutical & Biotech Companies, Academic & Government Research Institutes, Diagnostics Center, and Others) |
|
Countries Covered |
U.S., Canada, and Mexico |
|
Market Players Covered |
PerkinElmer Inc., FUJIFILM Visualsonics, Inc (A Subsidiary of FUJIFILM Corporation), Bruker, Hologic, Inc, Zeiss International, Agilent Technologies, Inc., Hamamatsu Photonics K.K., Vieworks Co., Ltd, Berthold Technologies GmbH & Co.KG , MILabs B.V, Trifoil Imaging, IVIM Technology Inc., MR Solutions, AI4R, Photon etc and among others |
Market Definition
Preclinical imaging is the use of various imaging techniques and technologies to visualize and study biological processes, diseases, and drug responses in animal models before they are tested in humans. It involves the non-invasive imaging of animals, typically rodents, such as mice and rats, to gain insights into the underlying mechanisms of diseases and to evaluate the efficacy and safety of potential therapies.
North America Preclinical Imaging Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Technological Advancement in the Field of Imaging
Preclinical imaging refers to the use of various imaging modalities to visualize and study the biological processes in animals before clinical trials. These systems helps researchers to gain insight about disease mechanisms, evaluate potential drug candidates, and monitor treatment efficacy. Technology advancement in the field of imaging is playing a crucial role in driving the growth of the North America preclinical imaging market.
- Increasing Number of Investments and Funding in Research and Development
The increasing number of investments and funding in research and development (R&D) is a significant driver of the growth of the North America preclinical imaging market. Organizations are allocating substantial resources to advance imaging technologies and support innovative research initiatives as the importance of preclinical imaging in drug discovery and development becomes more evident.
Opportunity
- Increasing Adoption of Imaging Systems for Preclinical Purpose
The pharmaceutical and biotechnology industries are continually searching for novel drug candidates to address unmet medical needs. Preclinical imaging allows for a more comprehensive understanding of potential drug candidates by visualizing their effects on living organisms. This helps in identifying promising candidates and eliminating those with unfavorable characteristics earlier in the drug development process, saving time and resources. The shift toward personalized medicine requires a more thorough understanding of individual patients' conditions. Preclinical imaging can be used to assess disease heterogeneity and tailor treatment approaches, leading to more effective therapies.
Restraint/Challenge
- Stringent Regulatory Framework for Product Approval
Regulatory bodies around the world have established strict guidelines and requirements for the approval of preclinical imaging products, which can create barriers for companies in the market and is a significant restraint factor on the growth of the North America preclinical imaging market.
Recent Developments
- In November 2022, Bruker announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging. This helped the organization develop more revenue
- In April 2022, PerkinElmer, Inc. announced the expansion of its in vivo imaging portfolio with the launch of the Vega imaging system. This increased the company's product portfolio and overall revenue
North America Preclinical Imaging Market Scope
The North America preclinical imaging market is segmented into four notable segments based on product, reagents, application, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Systems
- Services
On the basis of product, the market is segmented into systems and services.
Reagents
- Preclinical Optical Imaging Reagents
- Preclinical Nuclear Imaging Reagents
- Preclinical MRI Contrast Agents
- Preclinical Ultrasound Contrast Agents
- Preclinical CT Contrast Agents
On the basis of reagents, the market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents.
Application
- Research and Development
- Drug Discovery
- Bio-Distribution
- Cancer Cell Detection
- Bio-Markers
- Others
On the basis of application, the market is segmented into research and development, drug discovery, bio-distribution, cancer cell detection, bio-markers, and others.
End User
- Contract Research Organization
- Pharmaceutical & Biotech Companies
- Academic & Government Research Institutes
- Diagnostics Center
- Others
On the basis of end user, the market is segmented into contract research organization, pharmaceutical & biotech companies, academic & government research institutes, diagnostics center, and others.
North America Preclinical Imaging Market Regional Analysis/Insights
The North America preclinical imaging market is segmented into four notable segments based on product, reagents, application, and end user.
The countries covered in this market report are U.S., Canada, and Mexico.
U.S. is expected to dominate the North America preclinical imaging market because of the higher level of investments by various manufacturers and increasing technological advancements in the region. It is also due to the growing adoption of advanced technology and the launch of new products in this country.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Preclinical Imaging Market Share Analysis
The North America preclinical imaging market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major market players operating in the North America preclinical imaging market are PerkinElmer Inc., FUJIFILM Visualsonics, Inc (A Subsidiary of FUJIFILM Corporation), Bruker, Hologic, Inc, Zeiss International, Agilent Technologies, Inc., Hamamatsu Photonics K.K., Vieworks Co., Ltd, Berthold Technologies GmbH & Co.KG , MILabs B.V, Trifoil Imaging, IVIM Technology Inc., MR Solutions, AI4R, Photon etc and among others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA PRECLINICAL IMAGING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 STRATEGIC INITIATIVES
5 REGULATORY FRAMEWORK
5.1 REGULATORY SCENARIO IN U.S.
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING TECHNOLOGY ADVANCEMENT IN THE FIELD OF IMAGING
6.1.2 INCREASING NUMBER OF INVESTMENTS AND FUNDING IN RESEARCH AND DEVELOPMENT
6.1.3 INCREASING INCIDENCE OF CHRONIC DISEASES
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATORY FRAMEWORK OR PRODUCT APPROVAL
6.2.2 HIGH INSTALLATION AND OPERATIONAL COST OF PRECLINICAL IMAGING SYSTEMS
6.3 OPPORTUNITIES
6.3.1 INCREASING ADOPTION OF IMAGING SYSTEMS FOR PRECLINICAL PURPOSE
6.3.2 GROWING DEMAND FOR NON-INVASIVE SMALL-ANIMAL IMAGING METHODS
6.4 CHALLENGES
6.4.1 LACK OF SKILLED PROFESSIONALS FOR THE EFFECTIVE UTILIZATION OF PRECLINICAL IMAGING SYSTEMS
6.4.2 INTEGRATION OF IMAGING DEVICES WITH OTHER TECHNOLOGIES
7 NORTH AMERICA PRECLINICAL IMAGING MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 SYSTEMS
7.2.1 OPTICAL IMAGING SYSTEMS
7.2.1.1 BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS
7.2.1.2 STANDALONE FLUORESCENCE IMAGING SYSTEMS
7.2.1.3 OPTICAL + X-RAY/OPTICAL + CT
7.2.2 PRECLINICAL NUCLEAR IMAGING SYSTEMS
7.2.2.1 MICRO-POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS
7.2.2.2 MICRO-SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SYSTEMS
7.2.2.3 TRIPRODUCT (SPECT/PET/CT) SYSTEMS
7.2.3 MICRO-MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS
7.2.4 MICRO-COMPUTED TOMOGRAPHY (CT) SYSTEMS
7.2.5 MICRO-ULTRASOUND SYSTEMS
7.2.6 PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS
7.2.7 PRECLINICAL MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS
7.2.8 MAGNETIC RESONANCE SPECTROSCOPY IMAGING (MRSI)
7.3 SERVICES
8 NORTH AMERICA PRECLINICAL IMAGING MARKET, BY REAGENTS
8.1 OVERVIEW
8.2 PRECLINICAL OPTICAL IMAGING REAGENTS
8.2.1 BIOLUMINESCENT IMAGING REAGENTS
8.2.2 FLUORESCENT IMAGING REAGENTS
8.3 PRECLINICAL NUCLEAR IMAGING REAGENTS
8.3.1 PRECLINICAL PET TRACERS
8.3.2 PRECLINICAL SPECT PROBES
8.4 PRECLINICAL MRI CONTRAST AGENTS
8.4.1 GADOLINIUM-BASED PRECLINICAL MRI CONTRAST AGENTS
8.4.2 MANGANESE-BASED PRECLINICAL MRI CONTRAST AGENTS
8.4.3 IRON-BASED PRECLINICAL MRI CONTRAST AGENTS
8.5 PRECLINICAL ULTRASOUND CONTRAST AGENTS
8.6 PRECLINICAL CT CONTRAST AGENTS
8.6.1 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS
8.6.2 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS
8.6.3 GOLD NANOPARTICLES
8.6.4 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS
9 NORTH AMERICA PRECLINICAL IMAGING MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 RESEARCH AND DEVELOPMENT
9.3 DRUG DISCOVERY
9.4 BIO-DISTRIBUTION
9.5 CANCER CELL DETECTION
9.6 BIO-MARKERS
9.7 OTHERS
10 NORTH AMERICA PRECLINICAL IMAGING MARKET, BY END USER
10.1 OVERVIEW
10.2 CONTRACT RESEARCH ORGANIZATION
10.3 PHARMACEUTICAL & BIOTECH COMPANIES
10.4 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
10.5 DIAGNOSTICS CENTER
10.6 OTHERS
11 NORTH AMERICA PRECLINICAL IMAGING MARKET, BY COUNTRY
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA PRECLINICAL IMAGING MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 PERKINELMER INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 FUJIFILM VISUALSONICS, INC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 BRUKER
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 HOLOGIC, INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 AGILENT TECHNOLOGIES, INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 AI4R
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 ASPECT IMAGING LTD.
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENT
14.8 BERTHOLD TECHNOLOGIES GMBH & CO.KG
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 CUBRESA INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 HAMAMATSU PHOTONICS K.K.
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 IVIM TECHNOLOGY CORP.
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 KUB TECHNOLOGES INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 LI-COR, INC.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MEDISO LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 MILABS B.V.
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 MR SOLUTIONS
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 PHOTON ETC
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENT
14.18 SOFIE
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 TRIFOIL IMAGING
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 VIEWORKS CO., LTD.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENT
14.21 ZEISS INTERNATIONAL
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tablas
TABLE 1 NORTH AMERICA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 2 NORTH AMERICA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 3 NORTH AMERICA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 4 NORTH AMERICA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 5 NORTH AMERICA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 6 NORTH AMERICA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 7 NORTH AMERICA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 8 NORTH AMERICA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 9 NORTH AMERICA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 10 NORTH AMERICA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 11 NORTH AMERICA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 12 NORTH AMERICA PRECLINICAL IMAGING MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 13 U.S. PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 14 U.S. SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 15 U.S. SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 16 U.S. SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 17 U.S. OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 18 U.S. OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 19 U.S. OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 20 U.S. PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 21 U.S. PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 22 U.S. PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 23 U.S. PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 24 U.S. PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 25 U.S. PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 26 U.S. PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 27 U.S. PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 28 U.S. PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 29 U.S. PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 30 U.S. PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 31 U.S. PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 32 U.S. PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 33 U.S. PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 34 U.S. PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 35 U.S. PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 36 U.S. PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 37 U.S. PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 38 U.S. PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 39 U.S. PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 40 CANADA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 41 CANADA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 42 CANADA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 43 CANADA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 44 CANADA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 45 CANADA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 46 CANADA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 47 CANADA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 48 CANADA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 49 CANADA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 50 CANADA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 51 CANADA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 52 CANADA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 53 CANADA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 54 CANADA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 55 CANADA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 56 CANADA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 57 CANADA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 58 CANADA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 59 CANADA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 60 CANADA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 61 CANADA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 62 CANADA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 63 CANADA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 64 CANADA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 65 CANADA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 66 CANADA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 67 MEXICO PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 68 MEXICO SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 69 MEXICO SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 70 MEXICO SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 71 MEXICO OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 72 MEXICO OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 73 MEXICO OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 74 MEXICO PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 75 MEXICO PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 76 MEXICO PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 77 MEXICO PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 78 MEXICO PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 79 MEXICO PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 80 MEXICO PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 81 MEXICO PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 82 MEXICO PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 83 MEXICO PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 84 MEXICO PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 85 MEXICO PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 86 MEXICO PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 87 MEXICO PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 88 MEXICO PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 89 MEXICO PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 90 MEXICO PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 91 MEXICO PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 92 MEXICO PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 93 MEXICO PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
Lista de figuras
FIGURE 1 NORTH AMERICA PRECLINICAL IMAGING MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA PRECLINICAL IMAGING MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA PRECLINICAL IMAGING MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA PRECLINICAL IMAGING MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA PRECLINICAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA PRECLINICAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA PRECLINICAL IMAGING MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 NORTH AMERICA PRECLINICAL IMAGING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA PRECLINICAL IMAGING MARKET: SEGMENTATION
FIGURE 10 RISING PREVALENCE OF CHRONIC DISORDER AND ADVANCEMENTS IN IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA PRECLINICAL IMAGING MARKET FROM 2023 TO 2030
FIGURE 11 SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PRECLINICAL MARKET IN 2023 AND 2030
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA PRECLINICAL IMAGING MARKET
FIGURE 13 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY PRODUCT, 2022
FIGURE 14 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY PRODUCT, 2023-2030 (USD THOUSAND)
FIGURE 15 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 16 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 17 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY REAGENTS, 2022
FIGURE 18 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY REAGENTS, 2023-2030 (USD THOUSAND)
FIGURE 19 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY REAGENTS, CAGR (2023-2030)
FIGURE 20 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY REAGENTS, LIFELINE CURVE
FIGURE 21 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY APPLICATION, 2022
FIGURE 22 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 23 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 24 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 25 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY END USER, 2022
FIGURE 26 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 27 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 28 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 NORTH AMERICA PRECLINICAL IMAGING MARKET: BY SNAPSHOT (2022)
FIGURE 30 NORTH AMERICA PRECLINICAL IMAGING MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
